Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders

NCT01920087 is registered in ClinicalTrials.gov with Allodynic Therapeutics, Inc as lead sponsor.

NCT NCT01920087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01920087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders
Lead sponsor
Allodynic Therapeutics, Inc
Phase
Phase 2/3
Overall status
Withdrawn
Start date
March 31, 2014
Completion date
July 31, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical facial pain, atypical trigeminal neuralgia, neuropathic facial pain, neuropathic orofacial pain, persistent idiopathic facial pain